Denali therapeutics reports qtrly loss per share $0.56

Denali therapeutics reports second quarter 2020 financial results and business highlights.denali therapeutics inc- qtrly loss per share $0.56.denali therapeutics inc - collaboration revenue was $5.8 million for quarter versus $4.2 million for quarter ended june 30, 2019.

DNLI Ratings Summary

DNLI Quant Ranking